Folate pathway polymorphisms predict deficits in attention and processing speed after childhood leukemia therapy

Pediatric Blood and Cancer

Volumn 57, Issue 3, 2011, Pages 454-460

  Kamdar, Kala Y ^a,b   Krull, Kevin R ^c   El Zein, Randa A ^b,d   Brouwers, Pim ^a,e   Potter, Brian S ^f   Harris, Lynnette L ^a   Holm, Suzanne ^a   Dreyer, Zoann ^a   Scaglia, Fernando ^g   Etzel, Carol J ^d   Bondy, Melissa ^b,d   Okcu, M Fatih ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Childhood Cancer Epidemiology and Prevention Center   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Folate; Leukemia; Neurocognitive; Survivor

Indexed keywords

FOLIC ACID; GLYCINE HYDROXYMETHYLTRANSFERASE; METHIONINE SYNTHASE; METHIONINE SYNTHASE REDUCTASE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); THYMIDYLATE SYNTHASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; ANALYSIS OF COVARIANCE; ARTICLE; ATTENTION DEFICIT DISORDER; CANCER CHEMOTHERAPY; CANCER SURVIVOR; CHILD; COGNITION; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOLOGIC TEST; SCHOOL CHILD; STUDENT T TEST;

5-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE S-METHYLTRANSFERASE; ANTINEOPLASTIC AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD, PRESCHOOL; COGNITION DISORDERS; FEMALE; FOLIC ACID; GENOTYPE; HUMANS; INFANT; MALE; METABOLIC NETWORKS AND PATHWAYS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVORS;

EID: 79960174296     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23162     Document Type: Article

References (43)

1. Moleski M. Neuropsychological, neuroanatomical, and neurophysiological consequences of CNS chemotherapy for acute lymphoblastic leukemia. Arch Clin Neuropsychol 2000; 15: 603-630.
2. Peterson CC, Johnson CE, Ramirez LY, et al. A meta-analysis of the neuropsychological sequelae of chemotherapy-only treatment for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer 2008; 51: 99-104.
3. Buizer AI, de Sonneville LM, Veerman AJ. Effects of chemotherapy on neurocognitive function in children with acute lymphoblastic leukemia: A critical review of the literature. Pediatr Blood Cancer 2009; 52: 447-454.
4. Mitby PA, Robison LL, Whitton JA, et al. Utilization of special education services and educational attainment among long-term survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer 2003; 97: 1115-1126.
5. Spiegler BJ, Kennedy K, Maze R, et al. Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate. J Clin Oncol 2006; 24: 3858-3864.
6. Waber DP, Turek J, Catania L, et al. Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: Findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. J Clin Oncol 2007; 25: 4914-4921.
7. Montour-Proulx I, Kuehn SM, Keene DL, et al. Cognitive changes in children treated for acute lymphoblastic leukemia with chemotherapy only according to the Pediatric Oncology Group 9605 protocol. J Child Neurol 2005; 20: 129-133.
8. Carey ME, Hockenberry MJ, Moore IM, et al. Brief report: Effect of intravenous methotrexate dose and infusion rate on neuropsychological function one year after diagnosis of acute lymphoblastic leukemia. J Pediatr Psychol 2007; 32: 189-193.
9. Nathan PC, Whitcomb T, Wolters PL, et al. Very high-dose methotrexate (33.6g/m(2)) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P. Leuk Lymphoma 2006; 47: 2488-2504.
10. Brouwers P. Commentary: Study of the neurobehavioral consequences of childhood cancer: Entering the genomic era? J Pediatr Psychol 2005; 30: 79-84.
11. Cole PD, Kamen BA. Delayed neurotoxicity associated with therapy for children with acute lymphoblastic leukemia. Ment Retard Dev Disabil Res Rev 2006; 12: 174-183.
12. Vezmar S, Becker A, Bode U, et al. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 2003; 49: 92-104.
13. Vezmar S, Schusseler P, Becker A, et al. Methotrexate-associated alterations of the folate and methyl-transfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity. Pediatr Blood Cancer 2009; 52: 26-32.
14. Surtees R, Clelland J, Hann I. Demyelination and single-carbon transfer pathway metabolites during the treatment of acute lymphoblastic leukemia: CSF studies. J Clin Oncol 1998; 16: 1505-1511.
15. Quinn CT, Griener JC, Bottiglieri T, et al. Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer. J Clin Oncol 1997; 15: 2800-2806.
16. Quinn CT, Griener JC, Bottiglieri T, et al. Effects of intraventricular methotrexate on folate, adenosine, and homocysteine metabolism in cerebrospinal fluid. J Pediatr Hematol Oncol 2004; 26: 386-388.
17. Kishi T, Tanaka Y, Ueda K. Evidence for hypomethylation in two children with acute lymphoblastic leukemia and leukoencephalopathy. Cancer 2000; 89: 925-931.
18. Ramaekers VT, Blau N. Cerebral folate deficiency. Dev Med Child Neurol 2004; 46: 843-851.
19. Ramaekers VT, Hansen SI, Holm J, et al. Reduced folate transport to the CNS in female Rett patients. Neurology 2003; 61: 506-515.
20. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 476-483.
21. Moretti P, Peters SU, Del GD, et al. Brief report: Autistic symptoms, developmental regression, mental retardation, epilepsy, and dyskinesias in CNS folate deficiency. J Autism Dev Disord 2008; 38: 1170-1177.
22. Steinfeld R, Grapp M, Kraetzner R, et al. Folate receptor alpha defect causes cerebral folate transport deficiency: A treatable neurodegenerative disorder associated with disturbed myelin metabolism. Am J Hum Genet 2009; 85: 354-363.
23. Krull KR, Okcu MF, Potter B, et al. Screening for neurocognitive impairment in pediatric cancer long-term survivors. J Clin Oncol 2008; 26: 4138-4143.
24. Reitan R. The Halstead-Reitan neuropsychological test battery: Theory and clinical interpretation, 2nd edition. Tucson, AZ: Neuropsychology Press; 1993.
25. Trites RL. Neuropsychological test manual. Ottawa, Ontario, Canada: Royal Ottawa Hospital; 1977.
26. Wechsler D. Wechsler Intelligence Scale for Children, 3rd edition. San Antonio, TX: Psychological Corporation; 1991.
27. Benton AL, Hamsher K, Sivan AB. Multilingual Aphasi examination, 3rd edition. Iowa City, IA: AJA Associates; 1983.
28. Krull KR, Brouwers P, Jain N, et al. Folate pathway genetic polymorphisms are related to attention disorders in childhood leukemia survivors. J Pediatr 2008; 152: 101-105.
29. Hishida A, Matsuo K, Hamajima N, et al. Associations between polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and susceptibility to malignant lymphoma. Haematologica 2003; 88: 159-166.
30. Stover PJ. Physiology of folate and vitamin B12 in health and disease. Nutr Rev 2004; 62: S3-S12.
31. Robien K, Ulrich CM. 5, 10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: A HuGE minireview. Am J Epidemiol 2003; 157: 571-582.
32. Leclerc D, Wilson A, Dumas R, et al. Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria. Proc Natl Acad Sci USA 1998; 95: 3059-3064.
33. Summers CM, Cucchiara AJ, Nackos E, et al. Functional polymorphisms of folate-metabolizing enzymes in relation to homocysteine concentrations in systemic lupus erythematosus. J Rheumatol 2008; 35: 2179-2186.
34. Horie N, Aiba H, Oguro K, et al. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995; 20: 191-197.
35. Trinh BN, Ong CN, Coetzee GA, et al. Thymidylate synthase: A novel genetic determinant of plasma homocysteine and folate levels. Hum Genet 2002; 111: 299-302.
36. Krajinovic M, Robaey P, Chiasson S, et al. Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL. Pharmacogenomics 2005; 6: 293-302.
37. Copeland DR, Dowell RE, Jr., Fletcher JM, et al. Neuropsychological effects of childhood cancer treatment. J Child Neurol 1988; 3: 53-62.
38. Espy KA, Moore IM, Kaufmann PM, et al. Chemotherapeutic CNS prophylaxis and neuropsychologic change in children with acute lymphoblastic leukemia: A prospective study. J Pediatr Psychol 2001; 26: 1-9.
39. Buizer AI, de Sonneville LM, van den Heuvel-Eibrink MM, et al. Chemotherapy and attentional dysfunction in survivors of childhood acute lymphoblastic leukemia: Effect of treatment intensity. Pediatr Blood Cancer 2005; 45: 281-290.
40. Schwahn B, Rozen R. Polymorphisms in the methylenetetrahydrofolate reductase gene: Clinical consequences. Am J Pharmacogenomics 2001; 1: 189-201.
41. Durga J, van Boxtel MP, Schouten EG, et al. Folate and the methylenetetrahydrofolate reductase 677C→T mutation correlate with cognitive performance. Neurobiol Aging 2006; 27: 334-343.
42. Roffman JL, Weiss AP, Deckersbach T, et al. Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia. Schizophr Res 2007; 92: 181-188.
43. Ruiz JR, Castillo R, Labayen I, et al. Individual and combined effects of ApoE and MTHFR 677C/T polymorphisms on cognitive performance in Spanish adolescents: The AVENA study. J Pediatr 2010; 156: 978-984.